Company
MDRenal is a well-funded privately held biotechnology company focusing on the development of mass-spectrometry based tools for targeted metabolomics, the analysis of hundreds of metabolites in complex mixtures as blood or urine.
Metabolomics holds the promise of significantly reducing attrition rates in the drug discovery process by giving valuable early information for lead selection, on mechanism of action and in drug safety assessment.
At MDRenal we are using our extensive knowledge in biochemistry, organic chemistry, mass-spectrometry, and bioinformatics to create ground-breaking solutions for the rapid identification, quantification and interpretation of metabolite biomarkers in blood and urine.
Technology
MDRenal is currently tuning its technology for metabolite identification and data analysis into a complete bioanalytics platform to make mass-spectrometry based metabolomics easier and more accurate then ever.
The bioanalytical challenge of quantification and identification of biological matrix constituents are at the very heart of MDRenals product development. A mixture of short-, mid- and long term research driven projects addresses the metabolomics and personalized diagnostics markets with a series of tailored and innovative products.
We are currrently developing kits for the market’s fastest mass-spectrometric identification and quantification of hundreds of metabolites with broad metabolite coverage.
